Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative therapies for oncology and central nervous system disorders. The company's mission is to deliver durable efficacy, favorable safety, and real-world usability in its therapeutic offerings. Headquartered in Coral Gables, Florida, Relmada Therapeutics was founded in 2004 and is committed to building a pipeline that provides meaningful outcomes for patients and long-term value for shareholders.

The company's pipeline is primarily focused on two lead programs: NDV-01 and Sepranolone. NDV-01 is a sustained-release intravesical formulation of gemcitabine and docetaxel designed for non-muscle invasive bladder cancer (NMIBC), which is advancing into a Phase 3 registrational program expected to initiate in mid-2026. Sepranolone is a novel clinical candidate that targets compulsive behaviors by modulating GABAA receptor activity and is progressing toward a Phase 2 trial in Prader-Willi syndrome, also anticipated to begin in mid-2026.

Under the leadership of CEO Sergio Traversa, Relmada Therapeutics continues to advance its pipeline with recent notable activities including the appointment of Michael Quirk as Senior Advisor for the Sepranolone Program in June 2026 and presentations at industry conferences such as the Jefferies Global Healthcare Conference in May 2026. The company also reported its first-quarter 2026 financial results in May, and H.C. Wainwright initiated coverage with a buy rating in June 2026, reflecting its current market positioning as a clinical-stage firm focused on key regulatory milestones and broad clinical adoption.